 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...1011121314151617181920...6263» |
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
New P4 trial: MAFALDA-R: Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (clinicaltrials.gov) - Jun 12, 2023
P4, N=75, Not yet recruiting, Sponsor: Fundacion SEIMC-GESIDA
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Weight gain on dolutegravir: Association is not the same as causation. (Pubmed Central) - Jun 9, 2023
No abstract available
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Retrospective data, Journal, Adverse events: Prevalence and Patterns of Adverse Drug Events Among Adult Patients with Human Immune Virus Infection on Dolutegravir-Based Antiretroviral Drug Regimens in Amhara Comprehensive Specialized Hospitals, Northwest Ethiopia: A Multicenter Retrospective Follow-Up Study. (Pubmed Central) - Jun 7, 2023
All adverse events were mild and none was severe or life-threatening events. Therefore, we recommend the use of dolutegravir in clinical settings.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon. (Pubmed Central) - Jun 6, 2023
Preferred 3L regimen was dolutegravir?+?darunavir/r?+?tenofovir?+?lamivudine (51%) and median duration on 3L was 21 [17-32] months...Despite the high burden of reverse transcriptase inhibitor - and protease inhibitor boosted by ritonavir drug resistance, genotyping-guided 3L regimens is accompanied by virological success in most patients. This high efficacy, most likely due to use of high genetic barrier antiretrovirals, requires continuous adherence support alongside close monitoring for long-term effectiveness in similar programmatic settings.
- | Mycobutin (rifabutin) / Pfizer, Lupin, Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Journal: Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates. (Pubmed Central) - Jun 6, 2023
Our simulations support the common practice of maintaining the adjusted dosage of a drug for another 2 weeks after stopping an inducer. Furthermore, our simulations suggest that an inducer should be administered for at least 14 days before conducting interaction studies to reach maximal induction.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Dolutegravir-based regimens in the post-partum period. (Pubmed Central) - Jun 5, 2023
Furthermore, our simulations suggest that an inducer should be administered for at least 14 days before conducting interaction studies to reach maximal induction. No abstract available
- | Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Biomarker, Journal: Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. (Pubmed Central) - Jun 5, 2023
Two ABCC4 polymorphisms, rs899494 and rs1059751, were nominally associated with change in eGFR and uB2M/Cr, respectively, albeit in the opposite direction of previous reports. COL27A1 polymorphism was genome-wide significantly associated with change in eGFR.
- | Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
Journal: PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir". (Pubmed Central) - Jun 2, 2023
At six months follow-up visit, the patient had HIV-RNA below 30 copies/ml and CD4+ T cell count increased from 673 cells/ mm3 to 688 cells/ mm3. Close follow-up of this patient is ongoing.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Journal: No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study. (Pubmed Central) - Jun 2, 2023
Close follow-up of this patient is ongoing. ART-na
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial completion date, Trial primary completion date: Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS) (clinicaltrials.gov) - Jun 2, 2023
P1/2, N=92, Recruiting, Sponsor: The Aurum Institute NPC
ART-na Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy. (Pubmed Central) - Jun 1, 2023
No grade III/IV adverse events were reported, and there was no worsening of blood counts, liver or renal function test parameters. The pan-genotypic regimen of SOF?+?VEL is safe and effective in PLHA with HCV coinfection who are on dolutegravir-based ART.
- | Tivicay (dolutegravir) / ViiV Healthcare
New trial: Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment (clinicaltrials.gov) - Jun 1, 2023
P=N/A, N=50000, Recruiting, Sponsor: Elizabeth Glaser Pediatric AIDS Foundation
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens. (Pubmed Central) - May 31, 2023
Our study demonstrated that viral suppression improved after introducing dolutegravir, although the proportion of patients with viral load <50 copies/mL was lower than expected. Improved access to routine viral load examinations and continuous surveillance of the effectiveness of antiretroviral therapy should be considered.
- || Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Na (Pubmed Central) - May 31, 2023
Dolutegravir and darunavir showed similar efficacy in AIDS- and late-presenting patients. A higher risk of TD due to CNS toxicity was observed with dolutegravir, and a higher probability of treatment simplification with darunavir.
- || Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal: The State of the HIV Epidemic in the Philippines: Progress and Challenges in 2023. (Pubmed Central) - May 26, 2023
Pre-exposure prophylaxis in the form of emtricitabine-tenofovir disoproxil fumarate has been rolled out...The HIV epidemic in the Philippines requires a multisectoral approach and calls for sustained political commitment, community involvement, and continued collaboration among various stakeholders. In this article, we outline the current progress and challenges in curbing the HIV epidemic in the Philippines.
- || Vocabria (cabotegravir oral) / ViiV Healthcare, bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal: Synthetic Approaches to a Key Pyridone-carboxylic Acid Precursor Common to the HIV-1 Integrase Strand Transfer Inhibitors Dolutegravir, Bictegravir, and Cabotegravir. (Pubmed Central) - May 25, 2023
Presented herein is a literature and patent review of synthetic routes used to access the pharmaceutically important intermediate 6. The review highlights the ways in which small fine-tuned synthetic modifications have been used to achieve good yields and regioselectivity of ester hydrolysis.
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: CHARACTERISE - A Cross-sectional, Observational Study to Characterise the Transition to Dolutegravir-based Regimens in South Africa in Terms of the Emergence of Obesity, Viral Re-suppression and Integration Into Routine Programme Care (clinicaltrials.gov) - May 24, 2023
P=N/A, N=200, Completed, Sponsor: University of Witwatersrand, South Africa
The review highlights the ways in which small fine-tuned synthetic modifications have been used to achieve good yields and regioselectivity of ester hydrolysis. Enrolling by invitation --> Completed | N=375 --> 200 | Trial completion date: Jun 2023 --> Mar 2023 | Trial primary completion date: Jun 2023 --> Dec 2022
- | Tivicay (dolutegravir) / ViiV Healthcare, Cimduo (lamivudine/tenofovir disoproxil fumarate) / Cipla, Celltrion, Macleods, Viatris, Sun Pharma, Aurobindo, Hetero
Observational data, Retrospective data, Journal: Understanding the Uptake and Outcomes of Non-occupational Postexposure Prophylaxis Use Through an Online Medical Platform in China: Web-Based Cross-sectional Study. (Pubmed Central) - May 23, 2023
The 0% infection rate in this study demonstrated that online PEP could be a valuable risk-reduction option to improve HIV prevention service within China. However, further research is needed to better facilitate PrEP transition among online PEP users.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Comment on: Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. (Pubmed Central) - May 23, 2023
However, further research is needed to better facilitate PrEP transition among online PEP users. No abstract available
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: DO-REAL: Dolutegravir in Real Life in Lesotho (clinicaltrials.gov) - May 23, 2023
P=N/A, N=1433, Completed, Sponsor: Swiss Tropical & Public Health Institute
No abstract available Active, not recruiting --> Completed
- || Tivicay (dolutegravir) / ViiV Healthcare
Substitute ralte for dolutegravir and leave the drv/r and ETR. Probably most of the activity is given by the insti and ETR. (Twitter) - May 22, 2023
- || Selzentry (maraviroc) / ViiV Healthcare, Rukobia (fostemsavir) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir 50mg BID plus ETV 200mg BID plus maraviroc 600mg BID (previously tropism testing) but fostemsavir is an opcion (Twitter) - May 22, 2023
- | Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang, Tivicay (dolutegravir) / ViiV Healthcare
FDA event, Preclinical, Journal: Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study. (Pubmed Central) - May 22, 2023
Visualizations of the intermolecular interactions of Dolutegravir in the active sites of MAO-B and AChE revealed the formation of several stable hydrogen bonds. Overall, Dolutegravir was identified as a potential anti-AD drug, however further in vivo evaluations should be considered.
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: LoDoCA: Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV (clinicaltrials.gov) - May 22, 2023
P=N/A, N=500, Recruiting, Sponsor: Swiss Tropical & Public Health Institute
Overall, Dolutegravir was identified as a potential anti-AD drug, however further in vivo evaluations should be considered. Trial primary completion date: Jan 2023 --> Sep 2023
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria. (Pubmed Central) - May 21, 2023
The viral suppression rate was higher than the national average of 82%. Our findings support the recommendation of DTG-based regimen as the preferred 1L ART.
- | TBAJ-876 / Global Alliance for TB Drug Development
Trial completion, Enrollment change, Trial completion date: A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults (clinicaltrials.gov) - May 19, 2023
P1, N=28, Completed, Sponsor: Global Alliance for TB Drug Development
Our findings support the recommendation of DTG-based regimen as the preferred 1L ART. Recruiting --> Completed | N=44 --> 28 | Trial completion date: Jan 2023 --> Aug 2022
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. (Pubmed Central) - May 18, 2023
P3
Recruiting --> Completed | N=44 --> 28 | Trial completion date: Jan 2023 --> Aug 2022 The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Journal, Real-world evidence, Real-world: Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study. (Pubmed Central) - May 17, 2023
Our results confirm the real-world, long-term efficacy, tolerability and high genetic barrier of DTG?+?3TC in treatment-experienced PWH. Although scarce, mutations causing resistance to nucleosides and integrase can emerge.
- |||| Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Monotherapy, Head-to-Head: Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial 12/x (Twitter) - May 16, 2023
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Antiretroviral Therapy Intensification for Neurocognitive Impairment in HIV. (Pubmed Central) - May 15, 2023
The findings do not support empiric ART intensification as a treatment for NCI in PWH on suppressive ART. They also do not support that DTG adversely affects cognition, mood, or weight.
- | Pifeltro (doravirine) / Merck (MSD)
Trial initiation date: DoraDO: Doravirine Dose Optimisation in Pregnancy (clinicaltrials.gov) - May 15, 2023
P4, N=76, Not yet recruiting, Sponsor: University of Liverpool
They also do not support that DTG adversely affects cognition, mood, or weight. Initiation date: Jan 2023 --> Jun 2023
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
The current recommendation of #dolutegravir-based #ART is more favourable rather than #efavirenz, #emtricitabine, and #tenofovir disoproxil fumarate, when started in pregnancy https://t.co/TGLw2ZaEY3 #DataViz #visualabstract #HIV @TheLancetHIV @JudithCurrier @PaulSaxMD @HIVGov (Twitter) - May 9, 2023
- || Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal: Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir. (Pubmed Central) - May 8, 2023
DTG resulted in better lipid profiles after switching from EFV-based therapy, suggesting that this switch could benefit patients with a high risk of cardiovascular disease. However, it is essential to note that weight gain and increased waist circumference were also observed.
- | Tivicay (dolutegravir) / ViiV Healthcare
Retrospective data, Journal: Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. (Pubmed Central) - May 8, 2023
Women were less likely to receive dolutegravir than men. As dolutegravir was associated with improved outcomes, roll-out should continue, with a particular emphasis on inclusion of women.
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Journal: A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial. (Pubmed Central) - May 7, 2023
In this cohort of TW, switch to B/F/TAF was safe and metabolically neutral, though greater fat gain occurred on B/F/TAF. Further study is needed to better understand cardiometabolic disease burden in TW with HIV.
- Tivicay (dolutegravir) / ViiV Healthcare
Sustained viral load suppression among people living with HIV on Dolutegravir-based regimen in Southern Nigeria () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1647;
Further study is needed to better understand cardiometabolic disease burden in TW with HIV. Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Prevalence and predictors of persistent low-level HIV viraemia among people receiving Dolutegravir-based antiretroviral therapy in Southern Nigeria () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1640;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Changes in weight and body mass index associated with dolutegravir- and non-dolutegravir-based antiretroviral treatment regimens: a longitudinal analysis () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1586;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Outcomes from the Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) study at 6 months in Benin, Nigeria, and Uganda () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1517;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
High acceptability and preference for pediatric dolutegravir 10mg among children living with HIV in Nigeria at 1- and 6-month follow up, an observational study () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1479;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Viral load suppression in children living with HIV after pediatric dolutegravir optimization in Eswatini () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1396;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Dolutegravir in our youngest cohort: follow-up of genotype led antiretroviral optimization in unsuppressed children () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1351;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Improved virologic suppression in children living with HIV under the age of 5 in Tanzania after the initiation of a viremia clinic and pediatric dolutegravir () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1296;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Early effect of transitioning children to dolutegravir-based regimens on viral load suppression in Malawi () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1295;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Improved viral load suppression with transition to pediatric dolutegravir among ART-experienced children in Kenya and Cote d () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1275;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
24 week efficacy and safety of efavirenz- and dolutegravir-based antiretroviral therapy with isoniazid and rifapentine for tuberculosis preventive therapy (1HP and 3HP) in Thai people living with HIV () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1253;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Assessing the additional benefit of Tuberculosis Preventive Therapy among people living with HIV/AIDS on Dolutegravir-based antiretroviral therapy in two North Central states in Nigeria () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1114;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
96-week update: change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among virologically suppressed adults living with HIV () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1110;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Blood pressure among people living with HIV transitioning from efavirenz- to dolutegravir-based ART: a cohort study from Zimbabwe () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1062;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- Tivicay (dolutegravir) / ViiV Healthcare
Viral suppression in the era of transition to Dolutegravir-based therapy in Cameroon: children at high risk of virological failure () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_907;
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).